It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The cell nucleus is a tightly regulated organelle and its architectural structure is dynamically orchestrated to maintain normal cell function. Indeed, fluctuations in nuclear size and shape are known to occur during the cell cycle and alterations in nuclear morphology are also hallmarks of many diseases including cancer. Regrettably, automated reliable tools for cell cycle staging at single cell level using in situ images are still limited. It is therefore urgent to establish accurate strategies combining bioimaging with high-content image analysis for a bona fide classification. In this study we developed a supervised machine learning method for interphase cell cycle staging of individual adherent cells using in situ fluorescence images of nuclei stained with DAPI. A Support Vector Machine (SVM) classifier operated over normalized nuclear features using more than 3500 DAPI stained nuclei. Molecular ground truth labels were obtained by automatic image processing using fluorescent ubiquitination-based cell cycle indicator (Fucci) technology. An average F1-Score of 87.7% was achieved with this framework. Furthermore, the method was validated on distinct cell types reaching recall values higher than 89%. Our method is a robust approach to identify cells in G1 or S/G2 at the individual level, with implications in research and clinical applications.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Lisbon, Institute for Systems and Robotics (ISR), Instituto Superior Técnico (IST), Lisbon, Portugal (GRID:grid.9983.b) (ISNI:0000 0001 2181 4263)
2 University of Porto, Epithelial Interactions in Cancer (EPIC) Group, Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
3 University of Porto, Epithelial Interactions in Cancer (EPIC) Group, Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Institute of Biomedical Sciences Abel Salazar (ICBAS), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)
4 University of Porto, Epithelial Interactions in Cancer (EPIC) Group, Instituto de Investigação e Inovação em Saúde (i3S), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226); University of Porto, Faculty of Medicine, Porto, Portugal (GRID:grid.5808.5) (ISNI:0000 0001 1503 7226)